su zhou tong he yu cheng tou zi he huo qi ye you xian he huo - Net Worth and Insider Trading

su zhou tong he yu cheng tou zi he huo qi ye you xian he huo Net Worth

The estimated net worth of su zhou tong he yu cheng tou zi he huo qi ye you xian he huo is at least $750 Million dollars as of 2025-06-12. su zhou tong he yu cheng tou zi he huo qi ye you xian he huo is the 2101 Beneficial owner of Cutia Therapeutics and owns about 60,516,000 shares of Cutia Therapeutics (HKSE:02487) stock worth over $750 Million. Details can be seen in su zhou tong he yu cheng tou zi he huo qi ye you xian he huo's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that su zhou tong he yu cheng tou zi he huo qi ye you xian he huo has not made any transactions after 2024-11-01 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of su zhou tong he yu cheng tou zi he huo qi ye you xian he huo

su zhou tong he yu cheng tou zi he huo qi ye you xian he huo Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, su zhou tong he yu cheng tou zi he huo qi ye you xian he huo owns 1 companies in total, including Cutia Therapeutics (HKSE:02487) .

Click here to see the complete history of su zhou tong he yu cheng tou zi he huo qi ye you xian he huo’s form 4 insider trades.

Insider Ownership Summary of su zhou tong he yu cheng tou zi he huo qi ye you xian he huo

Ticker	Company	Transaction Date	Type of Owner
HKSE:02487	Cutia Therapeutics	2024-11-14	2101 Beneficial owner

su zhou tong he yu cheng tou zi he huo qi ye you xian he huo Latest Holdings Summary

su zhou tong he yu cheng tou zi he huo qi ye you xian he huo currently owns a total of 1 stock. su zhou tong he yu cheng tou zi he huo qi ye you xian he huo owns 60,516,000 shares of Cutia Therapeutics (HKSE:02487) as of November 1, 2024, with a value of $750 Million.

Latest Holdings of su zhou tong he yu cheng tou zi he huo qi ye you xian he huo

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
HKSE:02487	Cutia Therapeutics	2024-11-01	60,516,000	12.40	750,398,400

Holding Weightings of su zhou tong he yu cheng tou zi he huo qi ye you xian he huo

su zhou tong he yu cheng tou zi he huo qi ye you xian he huo Form 4 Trading Tracker

According to the SEC Form 4 filings, su zhou tong he yu cheng tou zi he huo qi ye you xian he huo has made a total of 2 transactions in Cutia Therapeutics (HKSE:02487) over the past 5 years, including 0 buys and 0 sells. The most-recent trade in Cutia Therapeutics is the sale of 0 shares on November 1, 2024, which brought su zhou tong he yu cheng tou zi he huo qi ye you xian he huo around $0.

Insider Trading History of su zhou tong he yu cheng tou zi he huo qi ye you xian he huo

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

su zhou tong he yu cheng tou zi he huo qi ye you xian he huo Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

su zhou tong he yu cheng tou zi he huo qi ye you xian he huo Ownership Network

Ownership Network List of su zhou tong he yu cheng tou zi he huo qi ye you xian he huo

No Data

Ownership Network Relation of su zhou tong he yu cheng tou zi he huo qi ye you xian he huo

su zhou tong he yu cheng tou zi he huo qi ye you xian he huo Owned Company Details

What does Cutia Therapeutics do?

Who are the key executives at Cutia Therapeutics?

su zhou tong he yu cheng tou zi he huo qi ye you xian he huo is the 2101 Beneficial owner of Cutia Therapeutics. Other key executives at Cutia Therapeutics include 2101 Beneficial owner Zhang Lele , 2201 Interest of corporation controlled by you Zhang Qiping , and 2201 Interest of corporation controlled by you su zhou tong yu tou zi guan li he huo qi ye you xian he huo .

Cutia Therapeutics (HKSE:02487) Insider Trades Summary

Over the past 18 months, su zhou tong he yu cheng tou zi he huo qi ye you xian he huo made no insider transaction in Cutia Therapeutics (HKSE:02487). Other recent insider transactions involving Cutia Therapeutics (HKSE:02487) include a net sale of 3,165,600 shares made by FIL Limited , a net sale of 3,165,600 shares made by Pandanus Partners L.P. , and a net sale of 3,165,600 shares made by Pandanus Associates Inc. .

In summary, during the past 3 months, insiders sold 0 shares of Cutia Therapeutics (HKSE:02487) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 10,397,200 shares of Cutia Therapeutics (HKSE:02487) were sold and 497,400 shares were bought by its insiders, resulting in a net sale of 9,899,800 shares.

Cutia Therapeutics (HKSE:02487)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cutia Therapeutics Insider Transactions

No Available Data

su zhou tong he yu cheng tou zi he huo qi ye you xian he huo Mailing Address

Above is the net worth, insider trading, and ownership report for su zhou tong he yu cheng tou zi he huo qi ye you xian he huo. Currently GuruFocus does not have mailing address information for su zhou tong he yu cheng tou zi he huo qi ye you xian he huo.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.